Multiple Ascending Dose Study of GMC-252-L-Lys Salt in Healthy Subjects and Type 2 Diabetics

Stopped It was considered by the sponsor that the study objective has been met by dosing 13 instead of 15 patients

Conditions

• Healthy
• Type 2 Diabetes Mellitus

Interventions

• DRUG: GMC-252-L-Lysine Salt
• OTHER: Placebo

Sponsor

Genmedica Therapeutics S.L.

Collaborators

• [object Object]